We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Pfizer | LSE:PFZ | London | Ordinary Share | COM STK USD0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.78 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMPFZ
RNS Number : 2153X
Pfizer Inc
22 February 2017
Pfizer Inc. to cancel listing in the United Kingdom
22 February 2017
Pfizer Inc. (NYSE:PFE) (the "Company") today announced that it has applied to the United Kingdom Listing Authority ("UKLA") to cancel the standard listing of the Company's common stock ("Common Stock") from the Official List of the UKLA and the cancellation of trading in the Company's Common Stock on the Main Market of the London Stock Exchange (together, the "Cancellation"), following a determination by the Company that there is limited trading or liquidity of its Common Stock on the Main Market of the London Stock Exchange. The Company also announced today that it will be cancelling the listing of its Common Stock from the SIX Swiss Exchange for the same reasons.
The effective date of the Cancellation is intended to be 23 March 2017. Following the de-listing, the Company will continue to list its Common Stock on the New York Stock Exchange under the symbol "PFE".
***
Contact
Media:
Joan Campion, + 1.212-733-2798
Joan.Campion@pfizer.com
Investor:
Chuck Triano, +1 212-733-3901
Charles.E.Triano@pfizer.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBXGDDISBBGRR
(END) Dow Jones Newswires
February 22, 2017 02:00 ET (07:00 GMT)
1 Year Pfizer Chart |
1 Month Pfizer Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions